ASO Visual Abstract: Socioeconomic Disparities in Pancreas Cancer Resection and Survival in the Veterans Health Administration Jonathan Pastrana Del ValleNathanael R. FillmoreJason S. Gold ASO Visual Abstract 07 February 2022 Pages: 3205 - 3205
Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Preoperative Factors Tipping the Scale of Decision-Making Giovanni MarchegianiStefano CrippaRoberto Salvia Pancreatic Tumors Open access 24 January 2022 Pages: 3206 - 3214
ASO Author Reflections: Surgery for Intraductal Papillary Mucinous Neoplasm: Predicting Risk for Better Patient Selection Giampaolo PerriGiovanni MarchegianiRoberto Salvia ASO Author Reflections 14 February 2022 Pages: 3215 - 3216
ASO Visual Abstract: Surgery for IPMN of the Pancreas—Preoperative Factors Tipping the Scale of Decision-Making G. MarchegianiS. CrippaR. Salvia ASO Visual Abstract 07 February 2022 Pages: 3217 - 3218
Prognostic Effect of Aberrant Right Hepatic Artery with Pancreaticoduodenectomy: Focus on Hepatic Recurrence Christopher W. MangieriCristian D. ValenzuelaClancy J. Clark Pancreatic Tumors 20 February 2022 Pages: 3219 - 3228
ASO Author Reflections: Aberrant Right Hepatic Artery Anatomy, an Independent Prognostic Factor for Hepatic Recurrence of Pancreatic Cancer Christopher W. MangieriClancy J. Clark ASO Author Reflections 11 February 2022 Pages: 3229 - 3230
ASO Visual Abstract: Prognostic Effect of Aberrant Right Hepatic Artery with Pancreaticoduodenectomy—Focus on Hepatic Recurrence Christopher W. MangieriCristian D. ValenzuelaClancy J. Clark ASO Visual Abstract 07 February 2022 Pages: 3231 - 3231
Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review Annabelle L. FonsecaHamza KhanFabian M. Johnston Pancreatic Tumors 23 January 2022 Pages: 3232 - 3250
ASO Visual Abstract: Disparities in Access to Oncologic Care in Pancreatic Cancer—A Systematic Review Annabelle L. FonsecaHamza KhanFabian M. Johnston ASO Visual Abstract 16 February 2022 Pages: 3251 - 3251
Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis: A Report from the Children’s Oncology Group Study AREN0534 Peter F. EhrlichBrett TornwallJeffrey S. Dome Pediatric Oncology 24 January 2022 Pages: 3252 - 3261
ASO Video Abstract: Kidney Preservation and Wilms Tumor Development in Children with Diffuse Hyperplastic Perilobar Nephroblastomatosis—A Report from the Children’s Oncology Group Study AREN0534 Peter F. EhrlichBrett TornwallJeffrey S. Dome ASO Visual Abstract 25 January 2022 Pages: 3262 - 3263
Delayed Gastric Emptying After Multivisceral Resection for Retroperitoneal Sarcoma Marco BaiaLorenzo ContiMarco Fiore Sarcoma 15 January 2022 Pages: 3264 - 3270
ASO Author Reflection: Delayed Gastric Emptying as a Sentinel Event of Severe Complications in Retroperitoneal Sarcoma Surgery Marco BaiaSandro PasqualiMarco Fiore ASO Author Reflections 22 January 2022 Pages: 3271 - 3272
ASO Video Abstract: Delayed Gastric Emptying After Multivisceral Resection for Retroperitoneal Sarcoma Marco BaiaLorenzo ContiMarco Fiore ASO Visual Abstract 10 January 2022 Pages: 3273 - 3273
Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution Maria DanieliFrancesco BarrettaAlessandro Gronchi Sarcoma 08 January 2022 Pages: 3274 - 3286
ASO Author Reflections: Outcome Improvement Over Time in Extremity and Trunk Wall Soft Tissue Sarcomas: To Whom the Merit? Maria DanieliAlessandro Gronchi ASO Author Reflections 12 January 2022 Pages: 3287 - 3288
ASO Visual Abstract: Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall—Outcome Improvement over Time at a Single Institution Maria DanieliFrancesco BarrettaAlessandro Gronchi ASO Visual Abstract 03 January 2022 Pages: 3289 - 3290
Extremity Soft Tissue Sarcoma: A Multi-Institutional Validation of Prognostic Nomograms Malcolm Hart SquiresCecilia G. EthunJ. Harrison Howard Sarcoma 11 January 2022 Pages: 3291 - 3301
ASO Author Reflections: Utility of Prognostic Nomograms for Extremity Soft Tissue Sarcoma Malcolm Hart SquiresJ. Harrison Howard ASO Author Reflections 25 January 2022 Pages: 3302 - 3303
ASO Visual Abstract: Extremity Soft Tissue Sarcoma—A Multi-institutional Validation of Prognostic Nomograms Malcolm H. SquiresCecilia G. EthunJ. Harrison Howard ASO Visual Abstract 28 January 2022 Pages: 3304 - 3305
Perineural Invasion is a Powerful Prognostic Factor for Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy Te-Wei LinHsiang-Ying LeeHsin-Chih Yeh Urologic Oncology 07 January 2022 Pages: 3306 - 3317
ASO Author Reflections: Prognostic Significance of Perineural Invasion in Upper Tract Urothelial Carcinoma Te-Wei LinHsin-Chih Yeh ASO Author Reflections 03 January 2022 Pages: 3318 - 3319
ASO Visual Abstract: Perineural Invasion is a Powerful Prognostic Factor for Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy Te-Wei LinHsiang-Ying LeeHsin-Chih Yeh ASO Visual Abstract 20 January 2022 Pages: 3320 - 3321
Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients Brice PaquetteElsa KalbacherBruno Heyd Peritoneal Surface Malignancy 07 January 2022 Pages: 3322 - 3334
ASO Author Reflections: Cisplatin- and Adrenaline-Based Intraperitoneal Chemotherapy Protocol for Ovarian Peritoneal Carcinosis: New Perspectives? Brice Paquette ASO Author Reflections 24 January 2022 Pages: 3335 - 3336
Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemorefractory Symptomatic Peritoneal Metastasis Chunmeng ZhangAsish PatelJason M. Foster Peritoneal Surface Malignancy 24 February 2022 Pages: 3337 - 3346
ASO Author Reflections: Palliative Management of Peritoneal Metastasis Exploring the Risks and Benefits of CRS/HIPEC, a Distinctly Different Context Than Early CRS/HIPEC Intervention With ‘Curative Intent’ Jason M. FosterChunmeng Zhang ASO Author Reflections 25 February 2022 Pages: 3347 - 3348
ASO Visual Abstract: Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemo-Refractory Symptomatic Peritoneal Metastasis Chunmeng ZhangAsish PatelJason M. Foster ASO Visual Abstract 28 February 2022 Pages: 3349 - 3350
Letter to the Editor: Comment on ‘‘Cytoreductive Surgery with or without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial’’ Vandré Cabral Gomes CarneiroNathalia Moreira Ramalho Gynecologic Oncology 15 February 2022 Pages: 3351 - 3352
The Debatable Role of HIPEC in Ovarian Cancer Eduardo PaulinoAndreia Cristina Melo Gynecologic Oncology 07 March 2022 Pages: 3353 - 3354
Enigma of Hyperthermic Intraperitoneal Chemotherapy with Interval Cytoreduction Surgery: Need to Push More Boundaries! Sriniket RaghavanSwapnil PatelDurgatosh Pandey Gynecologic Oncology 20 February 2022 Pages: 3355 - 3356
Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on “Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer—A Phase 3 Clinical Trial” B. NoiretN. BakrinC. Eveno Gynecologic Oncology 22 February 2022 Pages: 3357 - 3358
A Comment on a Recent Failed HIPEC Trial Luis ChivaPhilip HarterPedro Ramirez Gynecologic Oncology 15 February 2022 Pages: 3359 - 3360
Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer Pedro Antonio Cascales CamposAlida González Gil Peritoneal Surface Malignancy 07 March 2022 Pages: 3361 - 3362